Kleinman E, Laborada J, Metterle L, et al. What’s new in topicals for atopic dermatitis? Am J Clin Dermatol. 2022;23(5):595–603.

Article  PubMed  PubMed Central  Google Scholar 

Eichenfield LF, Silverberg JI, Hebert AA, et al. Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis. J Dermatolog Treat. 2024;35(1):2300354.

Article  PubMed  Google Scholar 

National Institute of Arthritis and Musculoskeletal and Skin Diseases. Atopic dermatitis. 2022. https://www.niams.nih.gov/health-topics/atopic-dermatitis. Accessed 28 Jan 2025.

Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–9.

Article  CAS  PubMed  Google Scholar 

Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: se ction 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.

Article  PubMed  PubMed Central  Google Scholar 

Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681–5.

Article  PubMed  Google Scholar 

Eichenfield LF, Silverberg JI, Hebert AA, et al. Targeting the aryl hydrocarbon receptor to address the challenges of atopic dermatitis. J Drugs Dermatol. 2024;23(2):23–8.

Article  PubMed  Google Scholar 

Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059–67.

Article  CAS  PubMed  Google Scholar 

Hwang J, Newton EM, Hsiao J, et al. Aryl hydrocarbon receptor/nuclear factor E2-related factor 2 (AHR/NRF2) signalling: a novel therapeutic target for atopic dermatitis. Exp Dermatol. 2022;31(4):485–97.

Article  CAS  PubMed  Google Scholar 

Organon. FDA approves VTAMA® (tapinarof) cream, 1% for the treatment of atopic dermatitis in adults and children 2 years of age and older [media release]. 16 Dec 2024. https://www.organon.com/.

Dermavant Sciences, Inc. VTAMA® (tapinarof) cream, for topical use: US prescribing information. 2024. https://www.fda.gov/drugs. Accessed 21 Jan 2025.

Dermavant Sciences. FDA approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults: first topical novel chemical entity launched for psoriasis in the U.S. in 25 years. 2022. https://dermavant.com/. Accessed 22 Jan 2025.

Keam SJ. Tapinarof cream 1%: first approval. Drugs. 2022;82(11):1221–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shirley M. Tapinarof cream 1% in plaque psoriasis: a profile of its use. Drugs Therapy Perspect. 2023;39(9):303–8.

Article  Google Scholar 

Dermavant Sciences. Dermavant announces approval of tapinarof in both psoriasis and atopic dermatitis in Japan [media release]. 25 Jun 2024. http://www.dermavant.com.

Bissonnette R, Saint-Cyr Proulx E, Jack C, et al. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research. J Eur Acad Dermatol Venereol. 2023;37(6):1168–74.

Article  CAS  PubMed  Google Scholar 

Stein Gold L, Rubenstein DS, Peist K, et al. Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications. J Am Acad Dermatol. 2021;85(3):e201–2.

Article  CAS  PubMed  Google Scholar 

Welichem Biotech Inc. Welichem and Stiefel, a GSK company, complete the acquisition by Stiefel of the novel anti-inflammatory agent, WBI-1001 [media release]. 31 Jul 2012. http://www.welichem.com.

Stiefel, Welichem Biotech Inc. Stiefel, a GSK company, enters into an agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis [media release]. 30 May 2012. http://www.stiefel.com.

Dermavant Sciences. Dermavant Sciences announces closing of transaction with GSK for purchase of rights to tapinarof [media release]. 21 Aug 2018. http://www.dermavant.com.

Dermavant Sciences. Dermavant enters into exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 15 Jan 2020. http://www.dermavant.com.

Torii Pharmaceutical Co., Ltd. Torii signs exclusive license agreement with JT for development and commercialization of tapinarof in Japan [media release]. 15 Jan 2020. https://www.torii.co.jp/en/.

Organon. Organon completes acquisition of Dermavant, including innovative dermatologic therapy, VTAMA® (tapinarof) cream, 1% [media release]. 28 Oct 2024. http://www.organon.com.

Dermavant Sciences. Dermavant Sciences announces appointment of Cyril Allouche as Chief Financial Officer and provides recent corporate update [media release]. 27 Mar 2019. http://www.dermavant.com.

Paller ASM, Hebert AA, Gonzalez ME, et al. Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis. Am J Clin Dermatol. 2025. https://doi.org/10.1007/s40257-025-00929-9.

Article  PubMed  PubMed Central  Google Scholar 

Igarashi A, Tsuji G, Fukasawa S, et al. Tapinarof cream for the treatment of atopic dermatitis: efficacy and safety results from two Japanese phase 3 trials. J Dermatol. 2024;51(11):1404–13.

Article  CAS  PubMed  Google Scholar 

Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91(3):457–65.

Article  CAS  PubMed  Google Scholar 

Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;60(92):44–7.

Article  Google Scholar 

Dermavant Sciences. Dermavant presents ADORING 3 LTE final data on complete skin clearance and treatment-free interval for VTAMA® (tapinarof) cream, 1% in adults and children as young as two years old with atopic dermatitis at 2024 Fall Clinical Dermatology Conference [media release]. 24 Oct 2024. http://www.dermavant.com.

Bissonnette R, Stein Gold L, Kircik L, et al. Skin clearance, treatment response off-therapy, and safety of tapinarof cream 1% once daily: results from ADORING 3, a 48-week phase 3 trial in adults and children down to 2 years of age with atopic dermatitis [abstract]. SKIN J Cutaneous Med. 2024;8(6): s460.

Article  Google Scholar 

Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89-98.e3.

Article  CAS  PubMed  Google Scholar 

Igarashi A, Tsuji G, Murata R, et al. A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol. 2024. https://doi.org/10.1111/1346-8138.17587.

Article  PubMed  PubMed Central  Google Scholar